Abstract |
We conducted a meta-analysis of randomized trials comparing regimens that included daily oral prednisone (P) in only one arm to investigate its impact on toxicities and outcomes in metastatic castration-resistant prostate cancer (mCRPC). Five trials were identified totaling 2939 patients, of whom 1471 were randomized to an arm not containing P and 1468 received therapy containing P. There was no difference between the non-P and P groups for severe toxicities (incidence rate ratio [ IRR]=0.82, p=0.712, I(2)=97.9%). When examining toxicities as a reason for discontinuing therapy, the non-P groups were not different from the P groups (relative risk [RR]=1.24, p=0.413, I(2)=86.8%). The non-P groups demonstrated no difference in OS compared to the P groups (HR=1.09, p=0.531, I(2)=79.7%). The meta-analysis is limited by the trial level design and small number of trials.
|
Authors | Charity J Morgan, William K Oh, Gurudatta Naik, Matthew D Galsky, Guru Sonpavde |
Journal | Critical reviews in oncology/hematology
(Crit Rev Oncol Hematol)
Vol. 90
Issue 3
Pg. 253-61
(Jun 2014)
ISSN: 1879-0461 [Electronic] Netherlands |
PMID | 24500033
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Copyright | Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Humans
- Male
- Odds Ratio
- Prednisone
(administration & dosage)
- Proportional Hazards Models
- Prostatic Neoplasms, Castration-Resistant
(drug therapy, mortality, pathology)
- Randomized Controlled Trials as Topic
|